Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum MethylGene Inc MYLGF

Healthcare Biotechnology

GREY:MYLGF - Post Discussion

MethylGene Inc > Dundee biotech outlook sees ‘ample room for upside
View:
Post by ftt998 on Jan 18, 2010 9:08am

Dundee biotech outlook sees ‘ample room for upside


https://biotuesday.ca/2010/01/18/dundee-biotech-outlook-sees-‘ample-room-for-upside’/
Comment by SanMiguelGto1 on Jan 20, 2010 11:50am
Does anyone know the month when the results of the clinical trials are expected?
Comment by pepman on Jan 20, 2010 10:23pm
The two phase I studies on MGCD265 are expected to end in March. Results should follow in June at ASCO. The phase I/II combo trial should be completed only in 2011.
MethylGene Inc
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Dealroom for high-potential pre-IPO opportunities